RCP appoints Professor Volmar Weissig to scientific advisory board
This article was originally published in Scrip
RCP Therapeutics, a US biopharmaceutical company specialising in the converging nanotechnology and regenerative medical markets, has appointedProfessor Volkmar Weissig to its scientific advisory board. Professor Weissig is associate professor of pharmacology at the department of pharmaceutical sciences, Midwestern University College of Pharmacy, Glendale, Arizona.
You may also be interested in...
The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.
The UK’s implementation of a new national licensing framework for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as the cause of an indefinite delay in the consultation process.
Hikma has temporarily stopped the roll-out of its rival to Advair Diskus in the US after it filed an amendment to its ANDA over packaging controls.